Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BNP Paribas Adjusts Northrop Grumman PT to $540 From $640, Maintains Outperform Rating

BNP Paribas Adjusts Northrop Grumman PT to $540 From $640, Maintains Outperform Rating

MT newswireMT newswire2026/10/06 13:17

09:17 AM EDT, 10/06/2026 (MT Newswires) -- Northrop Grumman (NOC) has an average rating of overweight and mean price target of $643.27, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

09:17 AM EDT, 10/06/2026 (MT Newswires) -- Northrop Grumman (NOC) has an average rating of overweight and mean price target of $643.27, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21